Astrazeneca Quotes

Goldman Sachs preaching about diversity so it can be at the front of the line for the next government bailout. It’s AstraZeneca waxing eloquent about climate change so it can secure multibillion-dollar government contracts for vaccine production. It’s State Street building feminist statues to detract attention from wage discrimination lawsuits from female employees, all the while marketing its exchange-traded fund with the ticker “SHE.” It’s Chamath Palihapitiya founding a social impact investment fund and criticizing Silicon Valley, even though he and his wealth are products of Silicon Valley, all to cover up for his prior tenure as an executive at Facebook who dreamed out loud about a private corporate military. Those companies and people use their market power to prop up woke causes as a way to accumulate greater political capital—only to later come back and cash in that political capital for more dollars.

Here is another example that demonstrates the tightly linked interests that both cause and treat cancer. In 1978, Imperial Chemical Industries (ICI), one of the largest companies in the world, specializing in agrochemicals and pharmaceuticals, developed the cancer drug tamoxifen. In 1985, along with the American Cancer Society, ICI founded the National Breast Cancer Awareness Month with the aim of promoting mammography as the most effective tool against breast cancer. In 1990 Imperial Chemical Industries was accused of dumping DDT and PCBs, known carcinogens, into the Long Beach and Los Angeles harbors. Zeneca, producer of tamoxifen, demerged from ICI in 1993, and later merged with Astra AB in 1999 to form AstraZeneca. Astra AB had developed the herbicide acetochlor, classified by the EPA as a probable carcinogen. In 1997 Zeneca purchased Salick Health Care, a chain of for-profit outpatient cancer clinics. Subsequently AstraZeneca launched a major publicity campaign encouraging women to assess their risk factors for breast cancer, downplaying the dangers of tamoxifen in order to create a market for its prophylactic, or chemopreventative, use and, more recently, for the breast cancer drug Arimidex (anastrozole), approved in 2002 and used as an alternative to tamoxifen (Arimidex went off patent in 2010).

Pushkala’s team knew that top-down approaches like those used by Lou Gerstner and Steve Jobs would backfire in this company as, unlike IBM and Apple, AstraZeneca wasn’t in crisis—although revenue and profits fell between 2011 and 2016. AstraZeneca is also a decentralized company, in which local leaders have substantial authority to accept, modify, or ignore orders from on high. So, rather than telling people what to do, Pushkala’s team took “a player-coach” approach. They implemented some key companywide efforts, but believed their success hinged on the cumulative impact of small systemwide and local changes. Most employees would join the effort because they wanted to, not because they had to. And the team believed that many of the best solutions would be tailored for tackling distinct local problems. As Pushkala put it, “Let us not solve world hunger; let us start eating the elephant in small chunks.

Gates Foundation currently holds corporate stocks and bonds in drug companies like Merck, GSK, Eli Lilly, Pfizer, Novartis, and Sanofi.69 Gates also has heavy positions in Gilead, Biogen, AstraZeneca, Moderna, Novavax, and Inovio. The foundation’s website candidly declares its mission to “seek more effective models of collaboration with major vaccine manufacturers to better identify and pursue mutually beneficial opportunities.

like, Moderna, Pfizer, AstraZeneca, Biontech, Sinovac, Novavax, CureVac, Johson & Johnson, Merck & Co, Inovio, and Cansino Biologics all use the same toxic and D.N.A. altering ingredients will absolutely make a killing!

After BlackRock created its Sustainability Accounting Standards Board, the firm quietly secured its status as the main financial administrator of the economic stimulus package during the COVID-19 pandemic, effectively playing the role of the government—and probably made a pretty penny for doing it. In January 2020, pharmaceutical giant AstraZeneca announced to much fanfare at (of course) the World Economic Forum in Davos a new investment commitment of $1 billion over ten years into environmental sustainability initiatives to fight climate change.

After BlackRock created its Sustainability Accounting Standards Board, the firm quietly secured its status as the main financial administrator of the economic stimulus package during the COVID-19 pandemic, effectively playing the role of the government—and probably made a pretty penny for doing it. In January 2020, pharmaceutical giant AstraZeneca announced to much fanfare at (of course) the World Economic Forum in Davos a new investment commitment of $1 billion over ten years into environmental sustainability initiatives to fight climate change. Just a couple of months later, it received a $1.2 billion grant—not a loan, but a grant—from US taxpayers to subsidize its development of for-profit vaccines.

after the second vaccination.93 The scientists warn that the precipitous drop in antibody levels will compromise the body’s ability to defend itself against COVID-19 if the individual is exposed to COVID. A second study published the same week confirms that the immune protection offered by two doses of Pfizer’s COVID-19 vaccine drops off after only two months!94 Another government-funded study in October confirms the decline in vaccine effectiveness in England95 finding that the reduction in transmission “declined over time since second vaccination, for Delta reaching similar levels to unvaccinated individuals by 12 weeks for [the AstraZeneca vaccine] and attenuating substantially for [Pfizer].

AstraZeneca. Tras negar en principio la posibilidad de arruinarle la vida a muchas personas con su vacuna, la compañía farmacéutica terminó admitiendo ante el Tribunal Superior que podía causar «síndrome de trombosis con trombocitopenia», lo que provoca que las personas tengan coágulos de sangre y un recuento bajo de plaquetas en sangre.

la farmacéutica AstraZeneca, miembro del Foro de Davos, acaba de admitir ante un tribunal británico que su vacuna contra el COVID-19 podría producir «un efecto secundario raro».